COMPANY
HydroGene Therapeutics
Funding and NIH signals
- NIH award NIH awarded $1.03M (SBIR Phase II 1R44HL187020-01, new, notice Sep 16, 2026); 2 NIH awards totaling $2.12M in the last 12 months. NIH RePORTER 1R44HL187020-01 (Sep 16, 2026)
Evidence (2 events)
- Sep 16, 2026 · NIH RePORTER 1R44HL187020-01
Organization: HYDROGENE THERAPEUTICS INC; City/State: HOUSTON, TX; Project number: 1R44HL187020-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-16; FY total cost (award amount): 1027445; Administering IC: National Heart Lung and Blood Institute; Project title: Non-viral hydrodynamic gene therapy for life-long correction of hemophilia; Organization type: Domestic For-Profits - Sep 10, 2026 · NIH RePORTER 1R44DK148200-01
Organization: HYDROGENE THERAPEUTICS INC; City/State: HOUSTON, TX; Project number: 1R44DK148200-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 1097036; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Developing Hydrodynamic Injection through Biliary System for the Treatment of Wilson's Disease; Organization type: Domestic For-Profits
- Sep 16, 2026 · NIH RePORTER 1R44HL187020-01